【24h】

The zenith aortic stent-graft: a 5-year single-center experience.

机译:天顶主动脉覆膜支架:5年的单中心经验。

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: To evaluate the efficacy and midterm results of the Zenith stent-graft in the treatment of abdominal aortic aneurysms (AAA). Methods: Since March 1994, 364 patients have undergone endovascular repair of infrarenal AAA. Of the 94 who were treated with the Zenith stent-graft from 1996 to 2002, 88 patients (82 men; mean age 72.6 +/- 6.5 years, range 47-88) with at least 6-month follow-up were analyzed. Sixty-one (69.3%) patients were considered at high risk for intervention; 7 ruptured AAAs were treated emergently. In all, 68 (77.3%) bifurcated stent-grafts (including 18 TriFab systems) and 20 aortomonoiliac configurations were used. Cumulative data on endoleak, migration, secondary procedures, and survival were evaluated with Kaplan-Meier analyses. Results: Implantation success was 97.7%; 2 (2.3%) access-related failures were converted to open repair (1 immediate, 1 at 3 months). There were 3 (3.4%) graft limb thromboses (2 immediate, 1 late), 3 (3.4%) cases of colon ischemia due to embolizationin 1 and hypogastric artery occlusion in 2, and 1 (1.1%) renal infarction due to embolism. Three (3.4%) patients died within 30 days. Eleven (12.5%) endoleaks and 1 (1.1%) late endograft migration were recorded. The 5-year cumulative endoleak and migration rates were 15% and 7%, respectively. Sixty-three (71.6%) patients did not present any complication related to the repair during a mean follow-up of 20.6 +/- 14.9 months (range 6-68); notably, no complications were associated with the 18 TriFab systems. Six (6.8%) secondary procedures were performed (31% 5-year cumulative secondary procedural rate). All 6 (6.8%) aneurysm-related deaths (the 3 perioperative, 2 from late AAA rupture, and 1 during a secondary procedure) and 14 of 18 (20.4%) non-aneurysm-related deaths occurred in high-risk patients; the 5-year cumulative survival rates were 57% for any death and 92% for aneurysm-related deaths. Conclusions: The Zenith stent-graft appears both safe and effective in terms of midterm outcome of endovascular aorticaneurysm repair.
机译:目的:评估Zenith支架移植物治疗腹主动脉瘤(AAA)的疗效和中期效果。方法:自1994年3月以来,对364例患者进行了肾下AAA血管内修复。在1996年至2002年用Zenith支架移植治疗的94例患者中,分析了88例患者(82例男性,平均年龄72.6 +/- 6.5岁,范围47-88),至少随访了6个月。六十一(69.3%)例患者被认为处于高干预风险;紧急治疗了7例破裂的AAA。总共使用了68(77.3%)个分叉的支架移植物(包括18个TriFab系统)和20个主动脉单ilia的构型。通过Kaplan-Meier分析评估了内漏,迁移,继发程序和生存率的累积数据。结果:植入成功率为97.7%; 2例(2.3%)与访问相关的故障被转换为公开维修(1例即时故障,3个月1例故障)。发生3例(3.4%)移植肢血栓形成(2例即刻,1例晚期),3例(3.4%)因栓塞1引起的结肠缺血和2例胃下动脉阻塞的病例以及1例因栓塞引起的肾梗塞(1.1%)。 30天内有三名(3.4%)患者死亡。记录到11次(12.5%)内漏和1次(1.1%)内移植后期迁移。五年累计内漏率和迁移率分别为15%和7%。 63例(71.6%)患者在20.6 +/- 14.9个月的平均随访期间(6-68岁)未出现与修复相关的任何并发症;值得注意的是,没有任何并发​​症与18个TriFab系统相关。进行了六次(6.8%)次要手术(31年的5年累积次要手术率)。所有6例(6.8%)与动脉瘤相关的死亡(3例围手术期,2例因AAA破裂导致的破裂,2例在继发过程中死亡)和18例(20.4%)与非动脉瘤相关的死亡中有14例发生在高危患者中; 5年累积生存率分别为:任何死亡57%,动脉瘤相关死亡92%。结论:就血管内主动脉瘤修复的中期结果而言,Zenith支架移植物既安全又有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号